Display Settings:

Format

Send to:

Choose Destination
Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. doi: 10.1517/13543784.17.11.1749 .

A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Author information

  • Genzyme Corp., Framingham, MA 01701-9322, USA. simon.fricker@genzyme.com

Abstract

BACKGROUND:

Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required.

OBJECTIVE:

The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in HSC homing and mobilization. Disruption of the SDF-1/CXCR4 axis by the CXCR4 anatagonist, plerixafor, is shown to improve HSC mobilization.

METHODS:

The molecular and in vivo pharmacology of plerixafor and subsequent clinical development is reviewed.

RESULTS/CONCLUSION:

Preclinical studies demonstrate that plerixafor is a selective antagonist of CXCR4 and can rapidly mobilize HSC. Clinical trials demonstrated improved HSC mobilization when plerixafor was included in the mobilization regimen. These data suggest the potential for a significant role for plerixafor in hematological disease.

PMID:
18922110
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk